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Not Inducible Is Not Enough*David J. Wilber, MDV entricular tachycardia (VT) following myo-cardial infarction (MI) arises from survivingmuscle ﬁbers that traverse the border and
penetrate more deeply into the scar core. Typically,
these ﬁbers are interconnected but insulated from
one another along much of their course, separated
by collagen and ﬁbrous tissue. This architecture dis-
rupts the normal pattern and sequence of rapid ven-
tricular activation and can produce critical regions
of slow conduction. In post-MI VT, these critical areas
are typically subendocardial but also occur in intra-
mural and epicardial scar. VT results when conduc-
tion block occurs at one of these sites, with slow
conduction around the block site and reentry of the
activation wave front from the opposite direction at
the original site of block. Circuit dimensions are large
(>2 cm2). In a given patient, multiple and widely
separated areas of slow conduction usually coexist,
giving the potential for multiple circuits and differing
QRS conﬁgurations on the surface electrocardiogram.
Catheter ablation for post-MI VT has been utilized
for more than 3 decades to decrease the risk for VT
recurrence, improve quality of life, and reduce health
care costs associated with treating recurrent epi-
sodes. The goal of VT ablation is to eliminate areas of
slow conduction where block and initiation of reentry
are most likely to occur. During the procedure, pro-
grammed ventricular stimulation (PVS) is used to
reproduce VTs in the laboratory at onset and conﬁrm
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paper to disclose.longer be induced at the end. Potential limitations of
noninducibility as a procedural endpoint include the
probabilistic nature of VT induction (variability in the
pacing sequence and ease of induction over varying
time periods, dependence on site of PVS and prox-
imity to circuits), the inability to induce VT at pro-
cedure onset in some patients, and a high rate (20% to
40%) of spontaneous VT recurrence despite post-
procedure noninducibility (1–3). Additionally, the
risk for repeated induction and termination of VT in
marginally stable patients after a long procedure may
lead physicians to forgo post-procedure PVS in the
interest of a patient’s safety. These limitations have
prompted many investigators to advocate additional
or alternative endpoints for VT ablation, including
complete elimination of fragmented and delayed po-
tentials in sinus rhythm (4,5) or extensive ablation of
the entire scar (6).
Despite the limitations of PVS as a guide to ablation
endpoints, a recent meta-analysis of eight observa-
tional studies evaluated post-MI VT ablation out-
comes, stratiﬁed by the results of post-procedure PVS
(7). The investigators reported a substantial reduction
in the risks for both recurrent VT and death in pa-
tients in whom inducible VT was rendered non-
inducible by ablation. The study did not examine
mortality as a time-dependent variable or adjust for
differences in other risk predictors. Thus, the possi-
bility could not be excluded that the ability to render
VT noninducible may simply reﬂect a less extensive
electroanatomical substrate associated with better
long-term outcomes.SEE PAGE 1954It is within this context that we can interpret
the ﬁndings from the study by Yokohawa et al. (8),
published in this issue of the Journal. This study,
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1961involving 7 international centers, provides a retro-
spective analysis of long-term mortality following
ablation in a consecutive cohort of 1,064 patients
with post-MI VT who underwent ablation between
2004 and 2012. The study population’s mean age was
68 years and mean ejection fraction was 31%. The
proportion of patients in whom the index procedure
represented the ﬁrst attempt at VT ablation, versus a
repeat procedure, is unclear. The burden of VT epi-
sodes before the index ablation also is unknown,
although prior amiodarone use in 55% of patients and
a history of VT storm in 31% suggest that a substantial
portion of patients had more advanced disease. The
approach to ablation largely reﬂected current prac-
tices, including use of three-dimensional mapping
systems and irrigated-tip ablation catheters, and a
multifaceted strategy that included both entrainment
mapping and substrate-guided approaches. The
study’s major goal was to determine whether non-
inducibility post-ablation independently predicted
survival.
Of the 1,011 patients with inducibility data avail-
able, 6% of patients had no VT induced at the
beginning of the procedure. At the procedure’s end,
of the 948 patients with initially inducible VT, 70%
had no VT induced, 19% still had inducible VT, and
the remaining 11% did not undergo post-ablation
PVS due to instability. Long-term follow-up data
regarding both the outcome of the index ablation and
subsequent mortality were available in 998 patients.
Overall, at 6 years, survival was 10% to 15%. Patients
without inducible VT at the end of the procedure had
signiﬁcantly better survival (unadjusted hazard ratio
[HR]: 0.77; 95% conﬁdence interval [CI]: 0.61 to 0.97),
with an estimated 4.7 months of life gained compared
with those in patients with persistently induced VT or
in whom post-ablation PVS was not performed.
Exclusion of patients without baseline inducible VT
negligibly affected this outcome. As expected, there
was a trend toward higher mortality in patients who
did not undergo post-procedure PVS due to insta-
bility, but this ﬁnding was not statistically signiﬁcant
(HR: 1.23; 95% CI: 0.84 to 1.82).
Multivariate Cox regression was used to determine
whether post-procedure noninducibility was an in-
dependent predictor of mortality relative to other
potential baseline comorbidities. An important study
limitation was that approximately one-third of the
initial cohort was excluded from analysis due to
missing data on predictor variables. Noninducibility
post-procedure remained an independent predictor
of long-term mortality (adjusted HR: 0.65; 95% CI:
0.53 to 0.79). Age, history of atrial ﬁbrillation, dia-
betes, and presentation with incessant VT were alsoindependent predictors. In this dataset, New York
Heart Association functional class and left ventricular
ejection fraction did not independently predict mor-
tality. This ﬁnding is surprising given previous data
indicating that ejection fraction is a strong predictor
of mortality in patients with post-MI VT following
ablation (2,9). This ﬁnding remains unexplained and
may reﬂect unrecognized collinearity among vari-
ables, and undetected residual confounders.
Recurrent VT during follow-up was signiﬁcantly
more likely in patients in whom VT remained induc-
ible as well as in patients who did not undergo post-
procedural testing (65% vs. 39%). Recurrence of any
VT post-ablation did not predict mortality in the un-
adjusted analysis and was only marginally signiﬁcant
when included as a time-ﬁxed variable in Cox
regression analysis (adjusted HR: 1.51; p ¼ 0.05), with
little impact on the better survival associated with
noninducibility. This ﬁnding contrasts with those
from prior studies that reported a signiﬁcant associ-
ation between post-ablation VT recurrence and mor-
tality (2,9). Reduction in the number of recurrent VT
episodes following ablation, rather than complete
elimination, occurs in a substantial proportion of
patients (2) and could also confer mortality beneﬁt.
As the authors acknowledge, data regarding the
number and timing of post-ablation VT recurrences
may have provided a more robust evaluation of the
independent impact of VT recurrence per se on mor-
tality, as the impact on time to death may depend on
the timing and number of VT recurrences.
Of greater importance, additional time-dependent
events during follow-up may substantially inﬂuence
mortality. These include: 1) changes in drug therapy,
including antiarrhythmic drugs; 2) intercurrent heart
failure (HF) decompensation or change in functional
class; and 3) changes in ischemic burden (progression
of coronary disease, new MI, coronary revasculariza-
tion). Data from a substudy of MADIT II (Multicenter
Automatic Deﬁbrillator Implantation Trial II) dem-
onstrated that in a large cohort of patients with prior
MI and left ventricular ejection fraction #30%,
hospitalization for new ischemic events or HF exac-
erbation during follow-up was associated with a
substantial increase in the risks for VT and death
relative to patients without these events (10). Recur-
rent HF hospitalizations during follow-up were the
most powerful predictor of mortality (11). We do not
know how many patients underwent additional
ablation during follow-up or whether such pro-
cedures affected VT recurrence and death. The cu-
mulative impact of these events during long-term
follow-up (and their distribution between groups)
may overwhelm the predictive value of variables
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1962gathered at the time of VT ablation, including
inducibility status. They also may potentially explain
the relatively limited impact of noninducibility on
long-term survival in this population.
What is most sobering in the data reported by
Yokokawa et al. (8) is the relentless nature of mor-
tality risk following VT ablation in a post-MI popula-
tion, irrespective of the outcome of PVS. The survival
curves separate after 1 year and remain relatively
parallel for the next 5 years, with an approximately
5% difference in estimated survival between groups
at most points in time. Survival after 6 years was
uncommon in either group. This does not negate the
value of ablation in this population, which included a
substantial portion of patients with relatively
advanced heart disease and drug-refractory VT and in
whom the primary therapeutic objective was the
reduction of symptoms and VT burden. Survival in
this population without ablation is unknown and
could have been considerably worse.
Enrollment was recently completed in a random-
ized trial comparing VT ablation to continued anti-
arrhythmic drug therapy in a post-MI population with
characteristics similar to those described in the pre-
sent study (VANISH [VT Ablation Versus Enhanced
Drug Therapy]; NCT00905853); completion of a
planned 5-year follow-up is underway. This trial will
likely provide additional insight into the potential
survival beneﬁt of VT ablation in the subgroup of
post-MI patients with more advanced substrate ab-
normalities and recurrent VT.
Patient characteristics and approaches to VT abla-
tion in this study reﬂect current clinical practice in
high-volume, experienced centers. The authors are to
be congratulated on an important contribution that
provides relatively complete mortality data and a
contemporary snapshot of factors inﬂuencing mor-
tality risk in one of the largest cohorts of post-
infarction VT assembled to date. Rendering baseline
inducible VT noninducible following ablation is
associated with a modest survival beneﬁt, indepen-
dent of most baseline risk factors. Thus, continued
use of noninducibility as one endpoint for VT ablation
seems reasonable. Whether improvements in the rateof post-procedure noninducibility alone will lead to
signiﬁcant improvements in survival is much less
clear. The results of this study should not discourage
the exploration of new additional/alternative end-
points for ablation. Developing better methods to
comprehensively address the arrhythmogenic sub-
strate present at the time of ablation remains a high
priority, including the use of high-resolution imaging
(12,13) and more effective catheter technology to
eliminate intramural and subepicardial VT sources
(14,15). However, it is likely that a substantial portion
of mortality risk (as well as risk for recurrent VT) in
the patient with post-MI VT ablation is determined by
events and therapies that occur during follow-up. We
need to increase our focus on the treatment and
prevention of HF progression and new ischemic
events, continued beta-blockade, judicious use of
antiarrhythmic drug therapy, and the role of heart
replacement therapy.
Finally, a strategy of early intervention soon after
the initial VT episode (and earlier in the clinical
course of ischemic VT) may provide a better test of
whether VT ablation can contribute to lower mortal-
ity. Two small randomized trials of treatment after
the ﬁrst VT episode in post-MI patients have
demonstrated signiﬁcantly reduced VT recurrences
following ablation compared with conventional
medical therapy, but no difference in mortality dur-
ing 2-year follow-up (16,17). Of interest, the mortality
at 2 years in both early intervention trials was
approximately 10% compared to 25% in the present
study, highlighting the potential adverse impact of
disease progression and multiple VT recurrences.
Whether earlier ablation can alter the prognosis of
ischemic VT and improve survival compared with
comprehensive medical therapy over extended
follow-up remains uncertain and is being evaluated
in 2 recently initiated randomized clinical trials
(NCT01547208 and NCT02130765).
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